-
Infection and Drug Resistance
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
Review
(5574) Total Article Views
Authors: Miceli MH, Chandrasekar P
Published Date January 2012 Volume 2012:5 Pages 9 - 16
DOI: http://dx.doi.org/10.2147/IDR.S22587
Received: | 16 November 2011 |
---|---|
Accepted: | 02 December 2011 |
Published: | 11 January 2012 |
1Oakwood Hospital and Medical Center, Dearborn, 2Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, MI, USA
Abstract: Liposomal amphotericin B is a "true" liposomal formulation of amphotericin B with greatly reduced nephrotoxicity and minimal infusion-related toxicity. This broad spectrum polyene is well tolerated and effective against most invasive fungal infections. In view of the current limitations on diagnostic capability of invasive fungal infections, most clinicians are often compelled to use antifungal drugs in an empiric manner; liposomal amphotericin B continues to play an important role in the empiric management of invasive fungal infections, despite the recent availability of several other drugs in the azole and echinocandin classes.
Keywords: invasive fungal infections, immunocompromised hosts, empiric therapy, polyenes, efficacy and safety
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Other articles by Dr Pranatharthi Chandrasekar
Readers of this article also read:
- Testimonials
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- Treatment of drug-resistant tuberculosis
- Lyme disease: the next decade